Clinical Trial Detail

NCT ID NCT02879994
Title Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.